tbuckley/cabot-search huggingface dataset:
Hyponatremia in clinically euvolemic patients receiving chemotherapy for solid tumours.
Authors: Kamel Farag, Jamal M Zekri, Reyad Dada
Journal: Journal of Clinical Oncology (2015)

e20700 Background: Biochemical hyponatremia is a common electrolyte abnormality in patients with cancer. Risk factors include chemotherapy, vomiting, diarrhea, hydration, narcotics and diuretics. We aim to study the frequency of hyponatremia in patients receiving chemotherapy for solid tumors with special emphasis on syndrome of inappropriate secretion of ADH (SIADH). Methods: This is a prospective study of 1254 consecutive patients receiving different types of out-patient chemotherapy between January 2013 and January 2014. Euvolemic patients with hyponatremia (Na<135 mmol/L) were also tested for Serum and urine osmolality and urinary Na excretion. Criteria of SIADH are: serum Osmolality < 275 mOsmol/kg, urine Osmolality > 100 mOsmol/kg and urinary Sodium > 30 mmol/L. Results: 104 patients receiving narcotics or diuretics were excluded. 1150 patients fulfilled the inclusion criteria. 105 (9.1%) patients had hyponatremia and are the subject of subsequent analysis. The table illustrates the frequency and degree of hyponatremia among patients receiving different chemotherapy regimens. Median age was 55 (19-75) year. 43.8% were males & 56.2% were females. Overall 68/105 (65%) fulfilled biochemical criteria of SIADH. 26/42 (62%), 13/25 (52%) and 29/38 (76%) of patients receiving cisplatin, other platinum and non-platinum based regimens respectively fulfilled biochemical criteria of SIADH. Conclusions: 9.1% of euvolemic patients receiving chemotherapy manifest a degree of hyponatremia. Cisplatin poses higher risk of hyponatremia than other regimens. About two thirds of hyponatremia in these patients is attributed to SIADH. Cisplatinbased chemotherapy (n=298) Carboplatin or oxaliplatin based chemotherapy (n=357) Non-platinum based chemotherapy (n=495) Total (n=1150) Have hyponatremia Mean serum Na in mmol/L (range) Grade of hyponatremia Mild (130-134.9) Moderate (125-129.9) Severe (<125) 42 (14.1%) 128.9 (123-133) 12 (4%) 29 (9.7%) 1 (0.3%) 25 (7%) 129.1 (126-133) 8 (2.2%) 17 (4.8%) None 38 (7.7%) 129.5 (127-133) 19 (3.8%) 19 (3.8%) None 105 (9.1%) 129.2 (123-133) 39 (3.4%) 65 (5.7%) 1 (0.09%)
Abstract P197: The Relationship Between Thyroid-Stimulating Hormone Levels and Lipoprotein Subfractions in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
Authors: Giuliano Generoso, Érique José Farias Peixoto de Miranda, Alessandra Carvalho Goulart, Márcio Sommer Bittencourt, Michael J Blaha, Steven Jones, Itamar de Souza Santos, Peter Toth, Krishnaji Kulkarni, Paulo Andrade Lotufo, Isabela M Benseñor
Journal: Circulation (2018)

Background and purpose: Although the relation between thyroid disorders and heart diseases had been described since decades ago, the association of thyroid-stimulating hormone (TSH) and lipoprotein...
FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
Authors: Edward Gane, Man-Fung Yuen, Qingyan Bo, Christian Schwabe, Tawesak Tanwandee, Sudip Das, Yuyan Jin, Lu Gao, Xue Zhou, Yifan Wang, sheng feng, dominik meinel, mingfen zhu
Journal: Journal of Hepatology (2019)
Survivin expression of tumor and lymphatic node in squamous cell lung carcinoma and relationship with prognosis.
Authors: Gamze Gokoz Dogu, Burcu Yapar Taskoylu, Aydin Demiray, Hakan Akca, Ferda Bir, Gokcen Demiray, Arzu Yaren, Ahmet Ergin
Journal: Journal of Clinical Oncology (2015)

e18537 Background: Lung cancer is the leading cause of cancer deaths. There is evidence that the apoptosis pathway has a prognostic and predictive significance in non- small cell lung carcinoma. Survivin is a member of a family of proteins that inhibits apoptosis; although it is normally expressed in differentiated cells, embryonic and fetal cells highly express it. In this study, we aimed to assess the relationship of the expression of survivin with the prognosis in squamous cell lung cancer. Methods: Fifty patients with pneumonectomy, lobectomy, wedge resection for squamous cell lung cancer were included in the study. Survivin levels in tumor and metastatic lymph nodes were examined by IHC and PCR methods. SPSS version 17 is used for statistical analysis. Results: In our study highly expressed survivin in tumour is stained in cytoplasma at all our patients. We established a significant relation between the survivin levels at tumour and the tumour differentiation (p = 0.02). Moreover the level of survivin in lymph nodes was higher at the patients with angiolymphatic invasion (p < 0.05). When evaluated, survivin levels in lymph nodes were found to be higher in stage III patients than stage II patients (p = 0.03). We determined a relation between both tumoral and lymph node survivin expression with smoking time (p = 0.12). There was no relation between the survivin levels in lymph node or tumor and the disease free survival or the overall survival (p > 0.05), but the survival time of the patients were shorter, in patients who has a higher survivin level in lymph node compared to the lower ones, though not statistically significant.Conclusions: For the first time in our study, different from other studies in literature, survivin levels in lymph nodes are evaluated, and it is observed that high expression may be linked with a shorter survival.We estimate that survivin can be used as a predictive marker. Comprehensive studies are needed for this topic.
Not all sensors are created equal: a framework for evaluating human performance measurement technologies
Authors: Brian Caulfield, Brenda Reginatto, Patrick Slevin
Journal: npj Digital Medicine (2019)

Abstract Recent years have witnessed an explosion in the number of wearable sensing devices and associated apps that target a wide range of biomedical metrics, from actigraphy to glucose monitoring to lung function. This offers big opportunities for achieving scale in the use of such devices in application contexts such as telehealth, human performance and behaviour research and digitally enabled clinical trials. However, this increased availability and choice of sensors also brings with it a great challenge in optimising the match between the sensor and a specific application context. There is a need for a structured approach to first refining the requirements for a specific application, and then evaluating the available devices against those requirements. In this paper we will outline the main features of such an evaluation framework that has been developed with input from stakeholders in academic, clinical and industry settings.
SAT-180-Hepatitis delta genotype 1 and 3 do not replicate after coinfection in the same cell in vivo
Authors: Hermanussen Lennart, Giersch Katja, Hendricks Lennart, Volz Tassilo, Lena Allweiss, Ansgar W. Lohse, Camille Sureau, John Casey, Maura Dandri, Marc Lütgehetmann
Journal: Journal of Hepatology (2019)
Effective targeted therapy for drug-resistant infection by ICAM-1 antibody-conjugated TPGS modified β-Ga<sub>2</sub>O<sub>3</sub>:Cr<sup>3+</sup> nanoparticles
Authors: Xu-Qi Kang, Gao-Feng Shu, Sai-Ping Jiang, Xiao-Lin Xu, Jing Qi, Fei-Yang Jin, Di Liu, Yong-Hong Xiao, Xiao-Yang Lu, Yong-Zhong Du
Journal: Theranostics (2019)

The prevalence of antibiotic resistance and lack of alternative drugs have posed an increasing threat to public health.Here, we prepared β-Ga 2 O 3 :Cr 3+ nanoparticles modified with ICAM1-antibody-conjugated TPGS (I-TPGS/Ga 2 O 3 ) as a novel antibiotic carrier for the treatment of drug-resistant infections.Methods: I-TPGS/Ga 2 O 3 were firstly characterized by measuring particle size, morphology, crystal structure, drug loading capacity, and in vitro drug release behaviors.The in vitro antibacterial activities of I-TPGS/Ga 2 O 3 /TIG were evaluated using standard and drug-resistant bacteria.The internalization of I-TPGS/Ga 2 O 3 was observed by fluorescence confocal imaging, and the expression levels of the efflux pump genes of TRKP were analyzed by real-time RT-PCR.In vitro cellular uptake and in vivo biodistribution study were performed to investigate the targeting specificity of I-TPGS/Ga 2 O 3 using HUEVC and acute pneumonia mice, respectively.The in vivo anti-infective efficacy and biosafety of I-TPGS/Ga 2 O 3 /TIG were finally evaluated using acute pneumonia mice.Results: It was found that TPGS could down-regulate the over-expression of the efflux pump genes, thus decreasing the efflux pump activity of bacteria.I-TPGS/Ga 2 O 3 with small particle size and uniform distribution facilitated their internalization in bacteria, and the TPGS modification resulted in a significant reduction in the efflux of loaded antibiotics.These properties rendered the encapsulated tigecycline to exert a stronger antibacterial activity both in vitro and in vivo.Additionally, targeted delivery of I-TPGS/Ga 2 O 3 mediated by ICAM1 antibodies contributed to a safe and effective therapy. Conclusion:It is of great value to apply I-TPGS/Ga 2 O 3 as a novel and effective antibiotic delivery system for the treatment of drug-resistant infections.
Self-reported sexual function measures administered to female cancer patients: A systematic review, 2008-2014.
Authors: Kathryn E Flynn, Diana D Jeffery, Barbara L. Andersen, Amy K Siston, Anuja Jhingran, Shirley R Baron, Jennifer B Reese, Deborah J Coady, Jeanne Carter, Lisa Catherine Barbera
Journal: Journal of Clinical Oncology (2015)

e20592 Background: Sexual concerns are common for women with cancer. To assist oncology clinicians and researchers in making an informed choice when selecting a patient-reported measure of sexual function (SF), we conducted a systematic review to identify and characterize self-reported SF measures used in studies of women with cancer. Methods: We followed 2009 PRISMA guidelines for systematic reviews. We searched PubMed and SCOPUS for studies on (or including) women with a cancer diagnosis, published from 2008-2014 in a peer-reviewed journal. Eligible studies used a self-reported measure of SF or a quality of life (QOL) measure with at least one SF item. Two reviewers abstracted each study following a standardized template; a third reviewer reconcilied differences. Results: Of 1,487 studies identified, 172 met inclusion criteria. The studies originated in 36 countries; 23% were from U.S.-based authors. Studies had been conducted in > 16 types of cancer, most studies described gynecologic (39%), breast (31%), or colorectal (19%) cancers. SF was the focus of 70% of studies, with the remainder examining QOL or comparing treatments. Almost 1/3 of studies used EORTC QLQ modules for SF, and 1/3 used the Female Sexual Function Inventory. In all, we identified 37 measures used in these studies that assess at least one domain of SF. Eight were dedicated SF measures developed with cancer patients; 3 of these have supporting evidence for validity, including psychometric evaluation (Sexual Activity Questionnaire, Sexual Function-Vaginal Changes Questionnaire, and PROMIS Sexual Function and Satisfaction measure). Nearly all studies demonstrated worse SF for women after cancer treatment or compared to non-cancer controls. Conclusions: There are many available measures for assessing SF that have been used in studies of women with cancer; however, relatively few have demonstrated evidence for validity in this population. This review provides information to assist in measure selection.
SAT-227-Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients
Authors: Elisabetta Degasperi, Enrico Galmozzi, Floriana Facchetti, Roberta D’ambrosio, Roberta Soffredini, Marta Borghi, Riccardo Perbellini, Massimo Iavarone, Angelo Sangiovanni, Pietro Lampertico
Journal: Journal of Hepatology (2019)
Severe asthma with blood hypereosinophilia associated with<i>JAK2</i>V617F mutation: a case series
Authors: Laure Tabèze, Sylvain Marchand-Adam, Raphaël Borie, Aurélien Justet, Clairelyne Dupin, Marie-Christine Dombret, Bruno Crestani, Camille Taillé
Journal: European Respiratory Journal (2019)

<b>Hypereosinophilia (blood eosinophil count &gt;1500 per mm<sup>3</sup>) in asthma patients may hide some rare myeloid or lymphoid neoplasms. Their identification has prognostic and therapeutic relevance because of the potential for targeted therapy.</b>http://bit.ly/2JCoVIA
Abstract P137: Effect of Obesity & T2DM on Cardiac Strain in Youth
Authors: Jessica E Haley, Zhiqian Gao, Philip Khoury, Stephanie N Stewart, Nicolas L Madsen, Thomas R Kimball, Lawrence M Dolan, Elaine M Urbina
Journal: Circulation (2017)

Introduction: Heart failure is a complication of long standing T2DM. Advanced echo measures can identify early sub-clinical systolic dysfunction in adults with T2DM. We hypothesized that subtle systolic dysfunction was present in young diabetics. Methods: Longitudinal strain was measured in 151 subjects with T2DM matched by age, race and sex to a lean (L=146), and non-diabetic (proven by OGTT) obese (O=162) control (23.0 ± 4.0 years, 35% male, 63% African American). Anthropometrics, BP, HR, fasting lipids, glucose and CRP and echocardiograms for LVM, shortening fraction (SF), global longitudinal 4-chamber strain (GLS) and strain rate in systole (GLSR) were obtained. ANOVA was performed to compare differences among groups for CV risk factors and strain measures and ANCOVA to determine if presence of T2DM remained an independent predictor of strain after correction for risk factors (full model=age, sex, race, presence of T2DM, BMI, SBP, DBP, HR and lab values). Results: CV risk factors worsened and there wa...
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis
Authors: Laura Cristoferi, Guido Carpino, Vincenzo Cardinale, Cristina Rigamonti, Diletta Overi, Nicola Zucchini, Monica Leutner, Mauro Viganò, Alessandra Nardi, Alessio Gerussi, Vincenzo Ronca, Massimiliano Cadamuro, Giulia Bonato, Domenico Alvaro, Eugenio Gaudio, David Jones, Pietro Invernizzi, George Mells, Marco Carbone
Journal: Journal of Hepatology (2019)
68Ga–Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma
Authors: Fahad Marafi, Sharjeel Usmani, Abdulredha Esmail
Journal: Clinical Nuclear Medicine (2019)

Abstract 68 Ga-PSMA is a promising tracer for both staging and detection of biochemical recurrence in prostate cancer. Prostate-specific membrane antigen is also expressed in the endothelium of neovasculature of various solid malignancies possibly due to tumor-associated angiogenic factors and endothelial cell sprouting. We report a case of 75-year-old man with metastatic cholangiocarcinoma to liver and lymph nodes progressing on chemotherapy. 68 Ga-PSMA PET/CT was performed to assess PSMA expression and showed additional bone and hepatic lesions compared with 18 F-FDG PET/CT. 68 Ga-PSMA expression in the metastatic cholangiocarcinoma potentially guides radionuclide legend therapy with α/β-emitters especially after enervation of all approved therapeutic options.
LBP-31-AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects
Authors: Manu Chakravarthy, Scharmen Confer, Joel Neutel, William Comb, Michael Hamill, Sean Carroll, Raffi Afeyan, Arun Sanyal
Journal: Journal of Hepatology (2019)
Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps
Authors: Bing Yan, Hongfei Lou, Yang Wang, Ying Li, Yifan Meng, Sihan Qi, Ming Wang, Lei Xiao, Chengshuo Wang, Luo Zhang
Journal: Journal of Allergy and Clinical Immunology (2019)
SAT-036-Prognostic implications of encephalopathy to adequately define differentiated stages of decompensated cirrhosis
Authors: Marta García Guix, Edilmar Alvarado, Alba Ardevol, rosa montañés, Berta Cuyas, bea de riba, carlos gonzalez, ana brujats, Maria Poca, Xavier Torras, Carlos Guarner, German Soriano, Candid Villanueva
Journal: Journal of Hepatology (2019)
THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort
Authors: Stephanie Popping, Carole Seguin-Devaux, Valeria Cento, Elena Knops, Robert de Knegt, Bart Rijnders, Veila Chiara Di Maio, Adolfo de Salazar, Orna Mor, Rolf Kaiser, David van de Vijver, Charles A.B. Boucher, Francesca Ceccherini-Silberstein, Federico Garcia
Journal: Journal of Hepatology (2019)
SAT-047-Easy surveillance method without need of special equipment for muscle volume loss in patients with chronic liver disease
Authors: Atsushi Hiraoka, Kojiro Michitaka, Eiji Tsubouchi, Tomoyuki Ninomiya, Yohei Koizumi, Hirooka Masashi, Masanori Abe, Bunzo Matsuura, Yoichi Hiasa
Journal: Journal of Hepatology (2019)
Loss of Microbial Topography Precedes Infection in Infants
Authors: Michael G. Surette, Dawn M. E. Bowdish
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

In their analysis, Jensen and colleagues point out that respiratory support variables alone are as good (or better) than oxygen variables.Keller and colleagues' report indicates that antenatal variables are also comparable (7).Conceptually, we like the physiologic approach of Svedenkrans and colleagues ( 13).An optimal research definition might include measurements of oxygenation, CO 2 elimination, and magnetic resonance imaging for the structural abnormalities that contribute to gas exchange abnormalities.For epidemiologic purposes, the definition does not seem to make much difference if it is consistently applied.For therapeutic studies, perhaps the outcome should be linked to the target of the therapy, such as parenchymal inflammation, airway injury, or pulmonary hypertension.
Reply
Authors: Mayank Sharma, Siddharth Singh, Douglas A. Simonetto
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. We thank Yan et al. for their interest in our study and for their comments.1 Placebo effect in medicine has been well known and documented.2 However, the main effect of placebo is observed in patient‐reported outcomes or subjective measures; the effect of placebo on objective biomarkers or hard outcomes such as mortality are likely minimal.2 Hence, in this study, when evaluating mortality as primary outcome, we believe that “placebo” and “no treatment” can be considered equivalent and be treated as a common comparator. With regard to differences in effect estimates from direct and indirect comparisons, we acknowledge that for some comparisons, there was a difference in the magnitude of effect observed from head‐to‐head trials and indirect comparisons from first‐order loops. In these instances, congruent with GRADE methodology,4 we rated the quality of evidence down for intransitivity (or inconsistency in effect estimates from direct and indirect comparisons). Likewise, evidence was rated down for imprecision in effect estimates either due to wide confidence intervals crossing unity or small number of events with failure to achieve optimal information size. This concept encompasses the authors’ concerns regarding reporting P values.
Abstract 18053: Dietary Quality Was Similar in Patients With Heart Failure Regardless Their Adherence to Sodium Restricted Diet
Authors: Misook L Chung, Debra K Moser, Junghee Kang, Terry A Lennie
Journal: Circulation (2017)

Introduction: Sodium restricted diet (SRD) is recommended for patients with heart failure to prevent worsening symptoms and early rehospitalization. However, there is a concern regarding whether fo...
THU-443-Unexpected pro-tumorigenic effect of the chemokine Cxcl10 by modulation of tumor stroma in a murine model of HCC
Authors: Elisa Fabiana Brandt, Janine Koehncke, Daniel Heinrichs, Theresa Hildegard Wirtz, Petra Fischer, Thomas Longerich, Christian Trautwein, Hacer Sahin, Marie-Luise Berres
Journal: Journal of Hepatology (2019)
TCTAP A-049 Clinical Experience of Percutaneous Coronary Intervention for Severely Calcified Coronary Artery Lesion with Diamondback 360 Coronary Orbital Atherectomy System
Authors: Junpei Koike, Atsushi Funatsu, Tomoko Kobayashi, Shigeru Nakamura
Journal: Journal of the American College of Cardiology (2019)
FRI-262-Genetic variants in the promotor region of the macrophage migration inhibitory factor are associated with severity of HCV-induced liver fibrosis
Authors: Theresa Hildegard Wirtz, Backhaus Christina, Petra Fischer, Bergmann Irina, Eggermann Thomas, Kurth Ingo, Christian Stoppe, Jürgen Bernhagen, Thomas Berg, Christian Trautwein, Marie-Luise Berres
Journal: Journal of Hepatology (2019)
FRI-461-Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis
Authors: Alvaro Diaz-Gonzalez, Ramon Vilana, Luis Bianchi, Ángeles García-Criado, Ernest Belmonte, Jordi Rimola, Anna Darnell, Carlos Rodriguez de Lope, Joana Ferrer, Carnen Ayuso, Leonardo Gomes da Fonseca, Maria Reig, Jordi Bruix, Alejandro Forner
Journal: Journal of Hepatology (2019)
Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1Ll Region
Authors: Rayjean J. Hung, Margaret R. Spitz, Richard S. Houlston, Ann G. Schwartz, John K. Field, Jun Ying, Yafang Li, Younghun Han, Xuemei Ji, Wei Chen, Xifeng Wu, Ivan P. Gorlov, Jie Na, Mariza de Andrade, Geoffrey Liu, Yonathan Brhane, Nancy Diao, Angela Wenzlaff, Michael P.A. Davies, Triantafillos Liloglou, Maria Timofeeva, Thomas Muley, Hedy Rennert, Walid Saliba, Bríd M. Ryan, Elise Bowman, Juan-Miguel Barros-Dios, Mónica Pérez-Ríos, Hal Morgenstern, Shanbeh Zienolddiny, Vidar Skaug, Donatella Ugolini, Stefano Bonassi, Erik H.F.M. van der Heijden, Adonina Tardon, Stig E. Bojesen, Maria Teresa Landi, Mattias Johansson, Heike Bickeböller, Susanne Arnold, Loic Le Marchand, Olle Melander, Angeline Andrew, Kjell Grankvist, Neil Caporaso, M. Dawn Teare, Matthew B. Schabath, Melinda C. Aldrich, Lambertus A. Kiemeney, H-Erich Wichmann, Philip Lazarus, Jose Mayordomo, Monica Neri, Aage Haugen, Zuo-Feng Zhang, Alberto Ruano-Raviña, Hermann Brenner, Curtis C. Harris, Irene Orlow, Gadi Rennert, Angela Risch, Paul Brennan, David C. Christiani, Christopher I. Amos, Ping Yang, Olga Y. Gorlova
Journal: Journal of Thoracic Oncology (2019)
Abstract 19785: Altered Qtc Intervals and Risk of Arrhythmias Arise in Mice Overexpressing Nitric Oxide Synthase Adapter Protein Nos1ap
Authors: Tatjana Williams, Daniel Oppelt, Paula Anahi Arias-Loza, Marco Abesser, Joachim Schmitt, Oliver Ritter
Journal: Circulation (2016)

Rationale: Cardiac depolarization is reflected by the QT interval duration. If prolonged, shortened or otherwise unregularly it may predispose individuals to ventricular tachycardia and sudden card...
THU-447-DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development
Authors: Matteo Lulli, Lorenzo Cavallini, Laura Gragnani, Caecilia Sukowati, Tommaso Mello, Andrea Galli, Veronica Ghini, Krista Rombouts, Vinicio Carloni
Journal: Journal of Hepatology (2019)